GlassScriptPhysician profile
Nilar Tun
NPI 1942621263
$9,716.14
in general payments reported to CMS, 2019-2025
31 companies · $1,719 in 2025
The $1,719 reported for 2025 was more than what 93% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,475 · 2020: $921 · 2021: $1,750 · 2022: $1,044 · 2023: $1,269 · 2024: $1,540 · 2025: $1,719.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,527.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,527.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,491.81 | 2019-2025 | Epclusa, Vemlidy |
| Esperion Therapeutics, INC. | $1,275.20 | 2020-2025 | Nexletol |
| Amgen INC. | $1,148.37 | 2019-2025 | Evenity, Prolia, Repatha |
| Novo Nordisk INC | $792.72 | 2019-2025 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $718.06 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $658.92 | 2019-2025 | Trelegy Ellipta, Shingrix |
| Abbvie INC. | $634.40 | 2021-2025 | Linzess |
| Lilly USA, LLC | $557.54 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $428.92 | 2019-2024 | Jardiance |
| Sanofi-Aventis U.S. LLC | $358.62 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $300.93 | 2019-2023 | Dificid |
| Otsuka America Pharmaceutical, INC. | $177.29 | 2024-2025 | Rexulti |
| Astellas Pharma US INC | $156.19 | 2019-2024 | Veozah |
| Ardelyx, INC. | $147.74 | 2024-2025 | Ibsrela |
| Pfizer INC. | $125.12 | 2020-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $125.00 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $104.92 | 2020-2025 | Zoryve |
| Ibsa Pharma INC. | $89.47 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $85.26 | 2024 | Voquezna |
| Radius Health, INC. | $57.93 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $57.37 | 2025 | |
| Hikma Pharmaceuticals USA | $45.66 | 2021 | |
| Eyevance Pharmaceuticals LLC | $31.03 | 2021 | |
| Sumitomo Pharma America, INC. | $25.45 | 2025 | Gemtesa |
| Amarin Pharma, INC. | $23.56 | 2023 | |
| Sanofi Pasteur INC. | $21.00 | 2020 | |
| Agios Pharmaceuticals, INC. | $19.10 | 2025 | Pyrukynd |
| Biohaven Pharmaceuticals, INC. | $18.18 | 2021 | |
| Eisai INC. | $15.32 | 2022 | |
| Genentech USA, INC. | $13.60 | 2021 | |
| Lupin INC. | $11.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nilar Tun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.